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Purpose: We recently demonstrated increased frequency and growth potential of late outgrowth endothelial progenitor
cells (OECs) in patients with neovascular age-related macular degeneration (nvAMD). This study investigated the effects
of short- and long-term in vitro inhibition of vascular endothelial growth factor (VEGF) Receptor-2 (VEGFR-2) signaling
by SU5416 and other inhibitors of the VEGF signaling pathway in OECs.
Methods: OECs, from the peripheral blood of patients with nvAMD, and human umbilical vein endothelial cells were
grown in the presence of SU5416, other VEGFR-2 tyrosine kinase inhibitors (TKIs), and inhibitors of phosphatidylinositol
3′-Kinase (PI3K)/protein kinase B (Akt) and protein kinase C (PKC) in complete angiogenic medium. Apotosis was
assessed after 48 h using the fluorescein isothiocyanate Annexin V method. Cell counts were performed for 10 days, and
features  of  senescence  were  analyzed  using  senescence-associated  β-galactosidase  staining,  the  telomeric  repeat
amplification protocol for telomerase activity, Southern blot analysis for mean telomere length, flow cytometric analysis
for cell-cycle arrest, and western blot for p53 and p21. Control OECs, cells treated for 7 days with inhibitors, as well as
naturally senescent OECs were analyzed for expression of different endothelial antigens, including VEGFR-2 and the
receptor for stromal cell-derived factor 1, chemokine receptor 4 (CXCR-4). Migration in vitro to VEGF and stromal cell-
derived factor 1 of OECs was assessed.
Results: SU5416, other VEGFR-2 TKIs, and inhibitors of PI3K, Akt, and PKC induced apoptosis, inhibited long-term
proliferation, reduced telomerase activity, and induced premature senescence and cell-cycle arrest in OECs as well as in
human umbilical vein endothelial cells. Naturally senescent cells and cells rendered senescent by VEGFR-2 TKIs had
reduced VEGFR-2 and CXCR-4 expression and demonstrated reduced migratory ability to VEGF.
Conclusions: This study demonstrates apoptosis upon short-term inhibition and inhibition of long-term survival of OECs
from patients with nvAMD by SU5416, presumably via PI3K/Akt and/or PKC-mediated reduction in telomerase activity
and subsequent induction of premature senescence, which is accompanied by impaired endothelial activity. Therefore,
induction of premature senescence in endothelial cells may represent a potential therapeutic target in nvAMD.
Age-related macular degeneration (AMD) is the leading
cause of irreversible visual impairment and blindness in the
older population of the developed world [1]. Until recently, it
was  assumed  that  cytokines,  such  as  vascular  endothelial
growth  factor  (VEGF),  promote  formation  and  growth  of
choroidal neovascularization (CNV), the anatomic correlate
of the neovascular form of AMD (nvAMD), by causing pre-
existing choroidal endothelial cells to sprout [2]. However,
VEGF can also mobilize endothelial progenitor cells (EPCs)
from the bone marrow and support differentiation of these
EPCs  into  mature  endothelial  cells  at  sites  of
neovascularization  [3-7].  In  animal  models  of  nvAMD,
several studies now show that a substantial fraction of vascular
cells participating in CNV are derived from the bone marrow
[8-12].  Clinical  evidence  for  a  role  of  EPCs  in  the
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development of CNV comes from the identification of the
EPC marker CD133 in specimens of surgically excised CNV
[13], detection of an increased number of circulating CD34+
hematopoietic cells in patients with nvAMD [14], and our own
findings of a significantly increased number of late outgrowth
endothelial progenitor cells (OECs) in the peripheral blood of
patients with nvAMD [15].
Activation by VEGF of its receptor VEGF receptor-2
(VEGFR-2)  promotes  proliferation  and  survival  of
endothelial  cells  via  the  phosphatidylinositol  3′-kinase
(PI3K)/protein kinase B (Akt) [16,17] and protein kinase C
(PKC)  [17,18]  signal  transduction  pathways.  Our  recent
investigations  have  shown  that  OECs  demonstrate  high
expression of VEGFR-2 and that their proliferation potential
positively correlates with VEGFR-2 expression [15].
Endothelial  cells,  like  most  normal  somatic  cells,
manifest a limited proliferation potential [19-21], and when
this potential is exhausted, cells enter a physiologic process
termed  “replicative  senescence”  (for  review  see  [22]).
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85Mechanistically,  repeated  cell  division  is  associated  with
progressive  shortening  of  telomeres,  and  synthesis  of
telomeres requires a reverse transcriptase called telomerase.
Although  somatic  cells  were  thought  to  rarely  possess
telomerase activity, endothelial cells stimulated to proliferate
in  vitro  show  marked  upregulation  of  telomerase  activity
[23], regulated by VEGF and other growth factors [23,24], via
their intracellular effectors Akt and PI3K [25]. In addition to
the alterations in replication, senescent endothelial cells also
show  other  characteristic  changes  in  gene  expression,
morphology, and function [22,26], for example, a marked
reduction in their migratory ability [27-29].
VEGF-neutralizing antibodies are the current treatment
standard for nvAMD. Other therapeutical options are being
investigated, including selective and nonselective VEGFR-2
tyrosine  kinase  inhibitors  (TKIs)  [30-34].  SU5416  was
developed as a potent and selective VEGFR-2 TKI [35] and
one of the first compounds to be evaluated in large-scale
clinical trials [36,37]. It was shown to possess long-lasting
inhibitory activity in vitro as well as in vivo [38] and to
increase tumor and endothelial cell apoptosis [39] as well as
decrease the size of experimental CNV [34]. Therefore, in the
present study, SU5416 was chosen to study the in vitro effect
of short- and long-term VEGFR-2 inhibition on apoptosis,
survival, telomerase activity, and cell-cycle status of OECs
from patients with nvAMD. In addition, we investigated the
hypothesis  that  pharmacologically  induced  premature
senescence  may  result  in  changes  in  levels  of  functional
proteins and/or a decrease in endothelial migration, a function
vital to the formation of CNV.
METHODS
Reagents:  SU5416,  KRN633,  KRN951  ZM323881,
Wortmannin, Ly 294002, and bisindolylmaleimide I were
purchased from Calbiochem (EMD Chemicals, San Diego,
CA).  Antibodies  against  p21  and  p53  were  from  Cell
Signaling Technology Inc. (Beverly, MA); goat polyclonal
antibody to β-actin was used as a loading control (Abcam Inc.,
Cambridge, MA). Cytokines VEGF and stromal cell-derived
factor-1 (SDF-1) were from Peprotech (Rocky Hill, NJ).
Isolation and culture of late outgrowth endothelial progenitor
cells:  We  have  previously  shown  robust  expansion  and
proliferation of OECs from a subset of patients with nvAMD
[15]. These AMD-affected participants were recruited from a
population of patients attending the National Eye Institute
(NEI) clinic in Bethesda, MD. The protocol for collection and
use  of  human  blood  samples  was  approved  by  the  NEI
Institutional Review Board, and all participants gave informed
consent to participate in the study.
Peripheral  blood  was  collected  in  a  tube  system
containing sodium heparin and a Ficoll Hypaque solution for
separation  of  blood  media  (Vacutainer  CPT,  Becton
Dickinson,  Franklin  Lakes,  NJ).  After  immediate  density
gradient centrifugation of the preparation, mononuclear cells
were  resuspended  in  endothelial  growth  medium-2
(EGM-2MV;  Cambrex,  Walkersville,  MD),  composed  of
endothelial cell basal medium-2 (EBM-2), 5% fetal bovine
serum (FBS), and growth factors (VEGF, basic fibroblast
growth  factor  [b-FGF],  insulin  growth  factor  [IGF],  and
epidermal growth factor [EGF]). Cells were plated at a density
of 2×106 cells/cm2 in 24-well plates precoated with fibronectin
(BD, Bedford, MA). The medium was changed daily for 7
days and on alternate days thereafter according to the protocol
established by Lin et al. [29]. OEC clusters, identified as well
circumscribed  monolayers  of  cobblestone-appearing  cells,
began  to  appear  between  7  and  30  days  of  culture.
Subconfluent cells were trypsinized and replated in vessels
coated with human fibronectin at a concentration of 10 μg/
cm2  (Chemicon,  Temecula,  CA).  OECs  were  further
subpassaged  and  expanded  until  cell  senescence,  as
determined by morphology changes, decrease in proliferation,
and  positive  staining  for  senescence-associated  β-
galactosidase  (SA-β-gal)  (BioVision  Research  Products,
Mountain View, CA) was reached. Human umbilical vein
endothelial  cells  (HUVEC,  Cambrex,  Walkersville,  MD)
were  similarly  cultured  in  EGM-2MV  medium  and  on
fibronectin-coated vessels. All experiments were performed
in EGM-2MV medium to mimic angiogenic conditions and
on  early  passage,  actively  proliferating,  subconfluent
nonsenescent cells. Endothelial cell phenotype was confirmed
by different methods (immunophenotyping for endothelial
cell-surface  marker  expression,  uptake  of  1,1'-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate (DiI)-acetylated low-density lipoprotein, staining
for Ulex europaeus lectin, and in vitro tube formation assays)
as described [15]. Prolonged passaging of OECs and HUVEC
was undertaken to obtain cells that had undergone replicative
senescence and were used as a control for naturally senescent
cells.
To  assess  cell  proliferation  under  different  inhibitory
conditions,  cells  were  plated  at  105  cells/well  in  six-well
plates. Inhibitor was added every other day, and cells were
subcultured to 80% confluency and reseeded at a density of
105 cells/well, with addition of fresh inihibitor. All inhibitors
had  been  dissolved  in  dimethyl  sulfoxide  (DMSO).  The
negative control consisted of DMSO solution (10 μl DMSO/
ml EGM-2MV) without inhibitor. Cell counts were performed
using a Neubauer counting chamber (Marienfeld, Germany)
and trypan blue stain (Invitrogen, Carlsbad, CA) for exclusion
of dead cells, according to the manufacturer’s instructions.
Cell  counts  were  performed  using  a  Neubauer  counting
chamber  (Marienfeld,  Germany).  0.1  ml  of  trypan  blue
(Invitrogen, Carlsbad, CA) stock (0.4% solution of trypan
blue in buffered isotonic salt solution) was added to 1 ml of
cells. The cell suspension was immediately loaded into the
counting chamber and cells that had taken up trypan blue were
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86considered  non-viable  and  excluded  from  counting.  All
experiments were repeated at least three times.
Apoptosis assay: Short-term survival of OECs and HUVEC
treated  with  SU5416  and  other  inhibitory  conditions  in
complete  EGM  was  assessed  by  collecting  floating  and
adherent cells incubated for 48 h and staining cells with the
fluorescein  isothiocyanate  (FITC)  Annexin  V/Dead  Cell
Apoptosis  kit  according  to  the  manufacturer’s  protocol
(Invitrogen). In brief, cells treated with different conditions
were  harvested  and  washed  twice  in  cold  PBS,  then
resuspended in annexin-binding buffer. FITC annexin V and
propidium iodide (PI) were added to the cell supension and
cells were incubated at room temperature for 15 min. After
the incubation period, annexin-binding buffer, was added an
samples were kept on ice until fluorescence activated cell
sorting  (FACS)  measurement.  After  FACS  acquisition,
percentage of apoptotic cells (Annexin V positive/Propidium
Iodide negative) was assessed using the Flowjo software (Tree
Star Inc., Ashland, OR).
Senescence assay: SA-β-gal activity was detected using the
Senescence Detection kit (Biovision, Mountain View, CA).
OECs and HUVEC grown on eight-well culture slides and
treated with different inhibitory modalities for different time
points were fixed and stained according to the manufacturer’s
protocol. In brief, cells were fixed for 10–15 min at room
temperature,  washed  twice  with  PBS,  then  incubated
overnight  in  staining  solution  at  37  °C.  Fixed  cells  were
observed under a microscope for development of blue color.
Detection  of  telomerase  activity:  Telomerase  activity  was
detected  in  OECs  and  HUVEC  inhibited  with  different
conditions for 3 or 7 days, using the TeloTAGGG Telomerase
PCR  ELISA  (Roche  Applied  Science,  Indianapolis,  IN),
which  utilizes  the  telomeric  repeat  amplification  protocol
(TRAP). Inhibitor was added every other day, and cells were
subcultured to 80% confluency, counted, and re-seeded at a
density of 105 cells/well, with addition of fresh inihibitor. The
negative control consisted of DMSO solution (10 μl DMSO/
ml EGM-2MV) without inhibitor. Reversibility of inhibition
of telomerase activity was tested by returning cells previously
inhibited for 7 days to complete EGM-2MV medium without
inhibitor for another 3 days. Cells were also counted at the
time of collection, and telomerase activity was adjusted for
cell number.
Southern blot analysis of mean telomere length: Analysis of
mean  telomere  length  of  cells  inhibited  for  7  days  was
performed  as  previously  published  [40].  Briefly,  genomic
DNA  was  isolated  from  harvested  cells,  electrophoresed,
blotted and transferred to positively charged Magnacharge
membranes (Osmonic, Minnetonk, MA). Membranes were
hybridized with 32P-(TTAGGG)3 as a telomeric probe using
Hybrisol  II  (Intergen,  Purchase,  NY).  Mean  terminal
restriction fragment (TRF) length was determined from. TRF
length  was  determined  from  scanned  autoradiographs  by
integrating the signal intensity above background over the
entire  TRF  distribution,  using  ImageQuaNT  software
(Molecular Dynamics, Sunnyvale, CA).
Western blotting: For western blot analysis for p21 and p53,
cells subjected to inhibitory treatment for 7 days were lysed
in lysis buffer containing 50 mM Tris/HCl (pH 7.5), 150 mM
NaCl,  1%  Triton  X-100,  1%  deoxycholate,  0.1%  sodium
azide, 1 mM ethylene glycol tetraacetic acid (EGTA), 0.4 mM
EDTA,  0.2  mM  sodium  orthovanadate,  1  mM
phenylmethylsulfonyl  fluoride  (PMSF),  and  one  protease
inhibitor tablet (Roche, Basel, Switzerland) per 10 ml. After
sonication, lysates were centrifuged at 10,000× g at 4 °C for
15 min, and protein concentration was measured using the
Bio-Rad  protein  assay  reagent  (Bio-Rad,  Hercules,  CA).
Equal amounts of lysates were subjected to sodium dodecyl
sulfate PAGE using 10% Tris-glycine gels (Invitrogen). After
electrophoresis,  protein  was  transferred  to  nitrocellulose
membranes.  Membranes  were  blocked  in  blocking  buffer
(50 mM Tris/HCl (pH 8.0), 2 mM CaCl2, 0.05% Tween-20,
and  5%  nonfat  dry  milk)  at  room  temperature  for  1  h.
Membranes were then incubated with 1:1,000 diluted rabbit
monoclonal  Antibody  (mAb)  against  p21,  1:1,000  diluted
antimouse p53, or 1:500 goat polyclonal antibody to β-actin-
loading control at 4 °C overnight and under constant agitation.
After primary antibody incubation, membranes were washed
twice in blocking buffer for 4 min, followed by incubation
with horseradish peroxidase (HRP)-conjugated antirabbit or
antigoat secondary antibody Santa Cruz (Santa Cruz, CA) at
room temperature for 45 min and under constant agitation.
Membranes were washed twice in blocking buffer for 4 min,
twice in washing buffer (50 mM Tris/HCl (pH 8.0), 2 mM
CaCl2, 80 mM NaCl, 0.05% Tween-20) for 4 min, incubated
for 4 min with chemiluminescence detection reagents (Pierce,
Rockford, IL), and finally exposed to Kodak Biomax film
(Kodak, Rochester, NY).
Flow cytometric analysis for cell cycle status (FACS) analysis
for  cell-cycle  status:  OECs  and  HUVEC  subjected  to
inhibitory conditions for 7 days were collected (floating and
adherent cells combined) and stained with Vybrant DyeCycle
Green  (Molecular  Probes,  Eugene,  OR)  according  to  the
manufacturer’s protocol. Briefly, 2 μl of Vybrant DyeCycle
Green  stain  was  added  to  flow  cytometry  tubes  each
containing 1 ml of cell suspension, followed by incubation at
37 °C for 30 min, protected from light. Stained samples were
immediately analyzed by FACS using 488 nm excitation and
green emission. After FACS acquisition, cell-cycle analysis
was performed using the cell-cycle platform of the Flowjo
software.
Flow cytometric analysis for endothelial cell markers analysis
for  endothelial  cell  markers:  For  FACS  analysis  of
nonsenescent  OECs,  naturally  senescent  OECs,  and  cells
rendered  prematurely  senescent  for  7  days  by  inhibitory
methods, mAbs against CD31-FITC, CD146-phycoerythrin
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and CXCR-4-PE (all BD PharMingen, San Jose, CA) and
VEGFR-2/Kinase insert domain receptor (KDR)-PE (R&D
Systems Inc., Minneapolis, MN) were used. Isotype-matched
immunoglobulin G (IgG) antibodies were used as a control.
OECs and HUVEC were trypsinized and incubated at 4 °C for
30 min with primary or isotype control antibody, washed, and
acquired by FACS. Analysis was performed using the FlowJo
software.
Migration  assays:  The  migratory  ability  of  nonsenescent
OECs,  naturally  senescent  OECs,  and  cells  rendered
prematurely  senescent  after  7  days  of  treatment  with
VEGFR-2  inhibitors  was  assessed  using  a  commercially
available  modified  Boyden  chamber  assay  (BD  BioCoat
Angiogenesis  System:  Endothelial  Cell  Migration,  Becton
Dickinson,  Franklin  Lakes,  NJ).  After  serum  starvation
overnight  in  EBM-2  +  0.1%  BSA,  cells  suspended  in
EBM-2+0.4% FBS were placed in the upper chamber, while
the  lower  chamber  contained  either  5  ng/ml  VEGF  in
EBM-2+0.4% FBS, 500 ng/ml SDF-1 in EBM-2+0.4% FBS,
or complete EGM-2MV. Cells were labeled using the Calcein
acetoxymethyl  ester  (AM)  dye  (Invitrogen)  after  22  h  of
migration,  and  a  fluorescence  plate  reader  (Synergy
microplate  reader,  Biotek,  Winooski,  VT)  was  used  to
quantify the migrated cells.
Statistical analysis: All experiments were performed at least
three times. Data are presented as mean±standard error of the
mean (SEM) and were analyzed with the Student t test for
paired data using the software StatView (SAS Institute, Casy,
NC). P values <0.05 were considered significant.
RESULTS
Induction  of  apoptosis  upon  short-term  treatment  with
SU5416: As shown in Figure 1, untreated HUVEC and OEC
cultures  contained  relatively  low  levels  (7.7±2.6%  and
6.6±1.5%, respectively) of apoptotic (Annexin V-positive, PI-
negative) cells. When increasing concentrations of SU5416 as
well as another VEGFR-2 TKI (4 μM KRN633) and inhibitors
of  the  Akt  (Wortmannin),  PI3K  (Ly  294002),  and  PKC
(bisidolylmaleimide I) pathways were added for 48 h, the
percentage  of  Annexin  V-positive  cells  was  significantly
increased compared to control cells, especially in OECs.
Decrease  in  proliferation  upon  long-term  treatment  with
SU5416: To analyze the fate of OECs and HUVEC upon long-
term inhibition of VEGFR-2 and its downstream signaling
pathways, inhibitors were added to the medium every other
day for up to 10 days. Treatment with SU5416 resulted in a
dose-dependent decrease in proliferation of OECs (Figure
2A). Generally, HUVEC demonstrated a higher proliferation
rate when compared to OECs, and proliferation of HUVEC
Figure 1. Effect of 48 h of inhibition of outgrowth endothelial progenitor cells and human umbilical vein endothelial cells on percentage of
apoptotic cells, as determined by flow cytometric analysis of Annexin V fluorescein isothiocyanate positive/propidium iodide (PI) negative
cells. Cells were grown in complete angiogenic medium (EGM-2MV) control conditions (10 μl DMSO/ml EGM-2MV), or in the presence
of 1, 3, and 10 μM SU5416, 4 μM KRN633, and inhibitors of the downstream mediators Akt (100 nM Wortmannin), PI 3-kinase (5 μM Ly
294002), and PKC (1 μM bisindolylmaleimide I). The graphs represent the mean±SEM cell number from three independent (OECs were
derived from three different patients, for HUVEC analysis was repeated at least twice) experiments. Student’s t-test for paired data was used
for statistical comparison between control and inhibitory conditions. P values <0.05 were considered significant and are denoted by an asterisk
in the figure.
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88was only decreased or inhibited when higher concentrations
of SU5416 were used (Figure 2B). Other TKIs of VEGFR-2
demonstrated similar inhibition of OEC and HUVEC long-
term  proliferation  (Figure  2C,D).  Inhibitors  of  VEGF/
VEGFR-2 downstream mediators, such as Akt (Wortmannin),
PI3K (Ly 294002), and PKC (bisindolylmaleimide I) also
markedly  inhibited  OEC  and  HUVEC  proliferation  in
complete angiogenic medium (Figure 2E,F).
Induction  of  premature  senescence  by  SU5416  and  other
inhibitors: After ex vivo expansion, OECs from all patients
as  well  as  HUVEC  eventually  (late  passages)  became
senescent, as demonstrated by a decrease in proliferation rate,
morphological changes (Figure 3B), and positive staining for
SA-β-gal (Figure 3E).
Early  passage  OECs  and  HUVEC  were  grown  under
inhibitory  conditions  as  previously  described,  and
experiments  were  terminated  after  either  3  or  7  days  for
cytochemical  analysis  of  SA-β-gal  expression.  SA-β-gal
expression  is  a  common  feature  of  senescent  cells  [41],
including  senescent  endothelial  cells  [42].  Morphological
signs  of  senescence,  such  as  decreased  cell  density  and
enlarged and flattened cell morphology, as well as increased
SA-β-gal expression appeared in single OECs after 3 days of
inhibitory conditions and became manifest in the majority of
cells after 6 to 7 days of inhibition. Inhibition for 3 days with
SU5416 (Figure 3C,G) and the inhibitors of Akt (Figure 3H),
PI3K (not shown), and PKC (Figure 3I) pathways induced
senescent morphology and expression of SA-β-gal in OECs.
To demonstrate irreversibility, cultures inhibited for 7 days
were returned to EGM-2MV medium without inhibition and
cultured for at least 3 more days. Cells previously treated with
inhibitors  maintained  proliferation  arrest  and  retained
senescent morphology (Figure 3C) and SA-β-gal expression
upon replacement of growth conditions with fresh EGM-2MV
medium  (not  shown).  Similar  results  were  obtained  with
HUVEC (data not shown).
Decrease of telomerase activity after treatment with SU5416:
We then tested whether these functional and morphological
signs of senescence were preceded by changes in telomerase
activity.  First,  telomerase  activity  in  nonsenescent  early-
passage OECs and HUVEC cultured in EGM-2MV medium
was assessed using TRAP. Telomerase activity was present in
OECs  and  HUVEC  to  a  similar  extent  (Figure  4A).
Telomerase activity was then analyzed after 3 or 7 days of
inhibitory  treatments.  Treatment  with  SU5416  for  3  days
suppressed telomerase activity in OECs in a dose-dependent
manner (Figure 4B). Telomerase activity was also decreased
after  inhibition  of  OECs  with  other  VEGFR-2  TKIs  and
inhibitors of VEGF downstream signals Akt (Wortmannin),
PI 3-kinase (Ly 294002), and PKC (bisindolylmaleimide I;
Figure 4C). Telomerase activity was similarly decreased in
HUVEC (data not shown) and remained decreased in both
OECs and HUVEC after 7 days of inhibition (see Figure 4D
for representative experiment). After returning inhibited cells
to complete medium without inhibitor at day 7, telomerase
activity demonstrated a concentration-dependent recovery at
day 10 with reduction of telomerase activity being irreversible
at higher concentrations (full recovery at 3 μM, no recovery
at 6 μM).
Lack of shortening of telomere length after SU5416 inhibition
for 7 days: Southern blot analysis did not reveal shortening of
telomere length after 7 days of inhibition with SU5416 in
HUVEC or OECs as compared to day 0 or day 7 controls
(representative Southern blot and TRF length in Figure 5A).
Upregulation of p21 and cell cycle arrest after treatment with
SU5416: Western blot analysis for p21 in OECs treated for 7
days  revealed  marked  upregulation  of  p21  in  response  to
SU5416 as well as other VEGFR-2 inhibitors and Akt, PI-3-
K, and PKC inhibition (Figure 5B). p53 remained unchanged
in all conditions.
To  study  the  cell-cycle  status  of  cells  treated  with
SU5416,  cells  were  incubated  with  the  DNA-selective
Vybrant  DyeCycle  Green  stain  and  frequency  histograms
were generated to reveal the phases of the cell cycle. SU5416
caused profound changes in the cell-cycle status after 7 days
of treatment, as revealed by an arrest of cells in the cell cycle
phase G0/G1 (Figure 5C).
Decrease of endothelial antigen expression and migratory
ability: Flow cytometric analysis was performed to detect
differences in endothelial cell protein expression in cells that
had become naturally senescent after repeated passaging or
prematurely  senescent  (as  determined  by  morphological
aspect, proliferation arrest, and SA-β-gal expression) during
VEGFR-2  inhibition.  Melanoma  cell  adhesion  molecule/
CD146,  Platelet  Endothelial  Cell  Adhesion  Molecule-1/
CD31,  ICAM-1,  and  ICAM-2  are  adhesion  proteins
participating in the recruitment of leukocytes to sites of tissue
injury  and  inflammation.  VEGFR-2  and  CXCR-4,  the
receptor for SDF-1, are both implicated in the migration of
endothelial cells and the recruitment of progenitor cells into
neovascular  tissues  [7,43-45].  Analysis  revealed  no
statistically significant difference in levels of CD146, CD31,
ICAM-1,  and  ICAM-2  between  nonsenescent,  naturally
senescent, and prematurely senescent OECs. VEGFR-2 and
CXCR-4  expression  levels,  however,  were  significantly
reduced  in  naturally  senescent  OECs  and  OECs  rendered
prematurely senescent by treatment with SU5416 for 3 days
compared  to  nonsenescent  OECs  (Figure  6A).  The  same
observation  was  made  for  HUVEC  and  other  VEGFR-2
inhibitors (data not shown).
VEGFR-2 and CXCR-4 are involved in endothelial cell
migration via their ligands VEGF and SDF-1. We therefore
performed  an  in  vitro  migration  assay  toward  VEGF  and
SDF-1 to analyze for differences in migratory ability between
nonsenescent, naturally senescent, and prematurely senescent
cells  (after  inhibitory  treatments).  The  migration  toward
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89Figure 2. Effect of different inhibitory conditions on long-term survival of late outgrowth endothelial progenitor cells and human umbilical
vein endothelial cells (HUVECs). Effect of SU5416 on proliferation of OECs (A) and HUVEC (B) in complete angiogenic medium
(EGM-2MV). Cells were grown in EGM-2MV control conditions (10 μl dimethyl sulfoxide [DMSO]/ml EGM-2MV), or in the presence of
3, 6, and 10 μM SU5416 added every 48 h. Long-term survival of OECs (C and E) and HUVEC (D and F) was similarly assessed in the
presence of other VEGFR-2 Tyrosine kinase inihbitors (TKIs; 10 μM ZM323881, 3 μM KRN951, 4 μM KRN633) and in the presence of
inhibitors of the downstream mediators Akt (100 nM Wortmannin), PI 3-kinase (5 μM Ly 294002), and PKC (1 μM bisindolylmaleimide I).
All cell counts were performed using the trypan blue exclusion method and a Neubauer counting chamber. The graphs represent the mean
±SEM cell number for three independent experiments (OECs derived from three independent (OECs were derived from three different patients,
for HUVEC analysis was repeated at least twice) experiments. Student’s t-test for paired data was used for statistical comparison between
control and inhibitory conditions at each time point. P values <0.05 were considered significant and are denoted by an asterisk in the figure).
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90Figure 3. Representative images of morphology of early passage control late outgrowth endothelial progenitor cells in complete angiogenic
medium containing dimethyl sulfoxide (10 μl/ml; A), late passage OECs (B), control early passage OECs after 3 days of inhibition with 10
μM SU5416 (C), and 3 days after returning SU5416 treated cells to EGM-2MV without inhibitor (D) are shown. Representative images of
senescence-associated beta-galactosidase staining (blue color) in early passage control OECs (E), late passage OECs (F) and early-passage
OECs treated with either 10 uM SU5416 (G), 100 nM Wortmannin (H) or 1 uM Bisindolylmaleimide I (I) for 3 days are shown.
Molecular Vision 2011; 17:85-98 <http://www.molvis.org/molvis/v17/a12> © 2011 Molecular Vision
91VEGF and EGM-2MV medium of naturally senescent OECs
and  OECs  rendered  prematurely  senescent  by  SU5416
treatment  was  significantly  reduced  compared  to
nonsenescent OECs (Figure 6B). While there was a trend
toward reduced migration to SDF-1 attractant, a statistically
significant difference between treatment groups could not be
Figure 4. Analysis of telomerase activity
as  assayed  by  the  telomeric  repeat
amplification protocol. A: Telomerase
activity was detected in early passage
nonsenescent late outgrowth endothelial
progenitor  cells  (OECs)  and  Human
Umbilical  Vein  Endothelial  Cells
(HUVEC)  cultured  in  complete
angiogenic  medium  (EGM-2MV).
Negative control represents telomerase
activity  of  heat-inactivated  OEC
samples, positive control corresponds to
the tumor cell sample provided by the
manufacturer  (TeloTAGGG
Telomerase  PCR  ELISA,  Roche
Applied Science, Indianapolis, IN). NS
denotes  not  statistically  significant
difference  in  telomerase  activity
between  HUVEC  and  OECs.  B:
Telomerase  activity  is  decreased  in
OECs  treated  with  3,  6  and  10  μM
SU5416 for 3 days compared to control
EGM-2MV (with the addition of 10 μl
DMSO/ml,  0  μM  SU5416).  C:
Telomerase  activity  is  decreased  in
OECs  treated  with  EGM-2MV
supplemented  with  inhibitors  SU5416
(6 μM), ZM323881 (10 μM), KRN633
(4  μM),  Wortmannin  (100  nM),  Ly
294002  (5  μM)  and
Bisindolylmaleimide I (1 μM) for 3 days
compraed  to  control  medium
(EGM-2MV with the addition of 10 μl
DMSO/ml). D: Recovery of telomerase
activity is dose-dependent. Telomerase
activity was assessed for control OECs
at day 0 and 7, OECs inhibited for 7 days
with SU5416 3 μM and 6 μM and for
OECs returned to EGM-2MV without
inhibitor for another 3 days after 7 days
of inhibition. Graphs A and C represent
the mean±SEM telomerase activity, B
and  D  the  mean  percentage  in
telomerase  activity  as  compared  to
control (medium without inhibitor in B,
medium without inhibitor after 10 days
of culture in D), for three independent
experiments each (OECs derived from
three different patients). Student’s t-test
for paired data was used for statistical
comparison  between  control  and
inhibitory  conditions.  *  indicates  a
statistically  significant  difference
(p<0.05) as compared to control.
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92Figure 5. Analysis of telomere length,
cell cycle proteins p21 and p53 and cell
cycle  status.  A:  A  representative
Southern  blot  analysis  of  telomere
length  of  control  Human  Umbilical
Vein Endothelial Cells (HUVEC) and
late outgrowth endothelial cells (OECs)
(in EGM-2MV or EGM-2MV with the
addition  of  10  μl  DMSO/ml)  and
HUVEC  and  OECs  inhibited  with
SU5416 at 3 and 6 μM for 7 days is
shown. B: A representative western blot
analysis  is  given  for  p21  and  p53  in
OECs treated with different inhibitory
conditions:  control=EGM-2MV  with
the  addition  of  10  μl  DMSO/ml,
EGM-2MV  supplemented  with
inhibitors  SU5416  at  3  and  10  μM,
KRN633 (4 μM), ZM323881 (10 μM),
Wortmannin  (100  nM),
Bisindolylmaleimide I (1 μM) and Ly
294002 (5 μM). Upper lane represents
p21,  second  lane  represents  p53  and
lower  lane  represent  corresponding
beta-actin loading controls. C: Presents
a  representative  flow  cytometric  cell
cycle  analysis  of  OECs  treated  with
SU5416,  using  Vybrant  DyeCycle
green.  Left  graph  represents  control
OECs (EGM-2MV with the addition of
10 ul DMSO/ml), right graph represents
OECs treated with SU5416 (6 μM) for 7
days. Green=G0/G1 peak area, blue=G2
peak area.
Molecular Vision 2011; 17:85-98 <http://www.molvis.org/molvis/v17/a12> © 2011 Molecular Vision
93revealed. Migration assays involving HUVEC gave similar
results (data not shown).
DISCUSSION
The results of this study indicate that blocking of the VEGF
receptor-2  signaling  with  the  potent,  selective,  and  long-
lasting compound SU5416 inhibits survival of OECs isolated
from patients with nvAMD as well as HUVEC by inducing
apoptosis  upon  short-term  exposure  and  premature
senescence and cell-cycle arrest upon long-term exposure.
The mechanism by which SU5416 as well as other VEGFR-2
TKIs accelerate OEC senescence appears to occur through
telomerase inactivation as early as 3 days after initiation of
inhibition.  Possibly,  telomerase  inactivation  is  mediated
through the PI3K/Akt and PKC pathways, as inhibition of
PI3K/Akt or PKC similarly results in senescence in these
cells.  Replicative  senescence  or  premature  senescence
induced by inhibitors is accompanied by impairment of OEC
activity, as evidenced by a significantly reduced migratory
ability.
Apoptosis  and  premature  senescence  seem  to  be  two
parallel  outcomes  activated  after  cells  suffer  irreparable
damage. How the cells choose between these two responses
may be dependent on the cell type, cell-cycle phase [46], the
degree of stress [47], or the age of cells [48].
Figure  6.  Effect  of  senescence  on
antigen expression and migration of late
outgrowth endothelial cells (OECs) and
Human  Umbilical  Vein  Endothelial
Cells  (HUVEC).  A:  Expression  of
different  antigens  by  control
nonsenescent OECs, OECs treated with
SU5416  (6  μM)  for  7  days  and  late-
passage naturally senescent OECs was
detected by flow cytometry. The graphs
represent  the  mean±Standard  error  of
the mean (SEM) percentage of positive
cells  for  OECs  derived  from  three
different  patients.  *  indicates  a
statistically  significant  difference
(p<0.05) as compared to control OECs.
B: Migration of control OECs, OECs
treated with SU5416 (6 μM) for 7 days
and  late-passage  naturally  senescent
OECs to Vascular Endothelial Growth
Factor  (VEGF),  Stromal  Cell  derived
Factor-1  (SDF-1)  and  complete
angiogenic  medium  (EGM-2MV)  is
shown. The graphs represent the mean
±SEM percentage of migrated cells (as
compared to cells migrated to EBM-2
basal medium without the addition of
serum  or  growth  factors)  for  OECs
derived from three different patients. *
indicates  a  statistically  significant
difference  (p<0.05)  as  compared  to
control OECs.
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94Accelerated  or  premature  senescence  is  increasingly
found  to  be  a  response  of  tumor  cells  to  several
chemotherapeutic agents and radiation (for review see [49]).
Inhibition of telomerase activity, which is activated in tumor
cells, seems to be an attractive target in cancer therapy [50,
51].  Once  thought  to  be  cancer-cell  specific,  telomerase
activity was found to be upregulated in endothelial cells too,
leading to a delay in replicative senescence of these cells
[23,24,52].  Moreover,  VEGF-dependent  activation  of
telomerase was also observed in vivo where it was required
for development of new capillaries in ischemic tissue [53].
Therefore, induction of premature endothelial cell senescence
might be an interesting target in anti-angiogenic therapy, e.g.,
for nvAMD.
Several previous studies have demonstrated acceleration
of senescence and proliferation arrest of EPCs and mature
endothelial cells in response to different stimuli [25,54-56].
Mechanisms that were identified in replicative as well as in
prematurely  induced  senescence  included  inactivation  of
telomerase activity [25,54,56], inhibition of PI3K/Akt [25],
modulation of cell-cycle regulatory proteins [56,57], and cell-
cycle arrest [57]. We herein demonstrate that induction of
premature senescence of OECs by SU5416 involves reduction
of telomerase activity, increased expression of p21, and G1
cell-cycle arrest. After 7 days of inhibition, shortening of
telomeres  was  not  yet  observed  in  this  study.  We  also
demonstrate  that  direct  inhibition  of  PI3K/Akt  and  PKC,
which  are  downstream  signal  transducers  of  VEGF  and
mediate proliferation and survival signals in endothelial cells
[16,58], similarly induce premature senescence, reduction of
telomerase activity, and increased expression of p21. These
results suggest that induction of premature senescence by
SU5416 and the other TKIs that were used in this study may
be through inhibition of these intracellular mediators.
It  remains  to  be  determined  whether  premature
senescence is mediated by selective inhibition of VEGFR-2
phosphorylation.  SU5416,  although  considered  to  be  a
selective  TKI,  also  exhibits  concentration-dependent
inhibition  of  other  growth  factor  receptors,  such  as  the
fibroblast growth factor (FGF) receptor, VEGF receptor 1
(flt-1) [59], insulin-like growth factor I receptor, Stem Cell
Factor  Receptor  c-kit  [60],  and  hepatocyte  growth  factor
receptor as well as intracellular kinases, such as sarcoma (Src)
[35,61]. Thus, SU5416 and the other TKIs may well induce
premature senescence by acting on several growth factor-
mediated pathways or even by other unknown mechanisms
independent of the tyrosine kinases.
Following irreversible growth arrest, little is known about
the fate of senescent endothelial cells. First, it is not clear how
premature senescence and apoptosis relate to each other. In
one report, senescent HUVEC, arrested in the G1 phase of the
cell cycle, displayed a considerable increase in spontaneous
apoptosis [57] and were also more prone to drug-induced
apoptosis  [62],  suggesting  that  senescence  may  facilitate
apoptosis. In another report, the baseline rate of apoptosis
remained unchanged during the process of senescence [63].
Second, do senescent cells remain metabolically active and do
they retain functional properties? Senescent fibroblasts mixed
with transformed epithelial cells stimulated the growth of the
latter in vitro and in tumor models [64]. Tumor cells senescing
in  response  to  chemotherapy  secreted  proteins  with  anti-
apoptotic, mitogenic, and angiogenic activities [65]. On the
positive side, senescent cells may also inhibit growth of tumor
or other neighboring nonsenescent cells by secreting growth
inhibitory  substances  [65,66].  Microarray  analysis
demonstrated overexpression of inflammatory and immune-
response genes in early-passage HUVEC, while those genes
were  repressed  at  senescence  [67].  We  have  shown  that
senescent  OECs  have  decreased  levels  of  VEGFR-2  and
CXCR-4, which could result in a lesser responsiveness to the
ligands,  as  demonstrated  by  reduced  migratory  ability  to
EGM-2MV and to VEGF alone. In senescent OECs, we did
not find changes in endothelial adhesion molecules, such as
ICAM-1,  a  key  protein  in  leukocyte  transendothelial
migration  previously  reported  to  accumulate  in  senescent
endothelial cells [68].
Finally, whether senescence is a feature of endothelial
cells in advanced CNV and whether treatment directed against
nvAMD may induce premature senescence of the endothelial
subtypes within active CNV has not been studied to date.
Therefore,  further  studies  will  be  directed  at  analyzing
features of senescence in endothelial cells inside experimental
CNV as well as a possible induction of premature senescence
in  vivo  by  different  treatment  strategies,  especially  those
directed against the VEGF/VEGFR-2 signaling pathway.
Presumably,  induction  of  premature  senescence  in
endothelial cells involved in the development of CNV may be
an  important  therapeutic  target  and/or  a  determinant  of
treatment response in nvAMD.
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